International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

How Superparamagnetic Nanoparticles are Revolutionizing the Global Fight Against Cancer

Tripti Kumar

GEMS New Millenium School

Abstract

The persistent threat of global cancer necessitates novel approaches in treating this disease by finding therapies to overcome toxicity of today's surgery, chemotherapy and radiation. Magnetically guided nanotherapeutics have emerged as one of the prominent candidates as the next generation site-specific and less-invasive method. Usually based on bioinert iron oxide (magnetite and maghemite) superparamagnetic nanoparticles that can be targeted at any area of interest by using an external magnetic field gradient, this approach is useful for a variety of applications from passive and active biochemical targeting to magnetic hyperthermia (induced cell death using time-varying magnetic field) to T2 contrast agents for MRI applications that represent theranostics by integrating therapy and diagnosis.

However, translation of this approach to clinical setting continues to face issues with, inter alia, the immune response from the reticuloendothelial system, poor external magnetic field depth penetrability, potential long term toxicity issues, manufacturing guidelines.

We review behaviour of magnetically targeted nanoparticles within tumour microenvironment, and how they may fit into personalized oncology platforms and conclude that magnetic targeting holds promise as a promising paradigm for a high efficacy, low-toxicity therapeutic solution.

1. Introduction

Although cancer research has come a long way in recent decades, producing a plethora of potential drugs in this time, and billions of dollars in investment have poured into developing new therapies, this persistent global health challenge still represents a formidable foe. An aging world population, an increase in exposure to known carcinogens, and changing human behaviour contribute to rising numbers of cancer patients each year and this growth can only be exacerbated going forward. What cancer needs more than any other weapon in the oncologist’s arsenal, is space.

Standard treatments, such as surgical resection, which involve removal of a significant amount of normal tissue adjacent to a tumour, along with the whole tumour mass, systemic administration of powerful chemotherapies, or even external-beam radiation, suffer from design flaws inherent to their basic concept. Chemo treatment affects rapidly dividing healthy cells, such as bone marrow, hair follicles and the GI tract, while targeting healthy tissue on its path towards a tumour may damage surrounding structures, which is problematic in some cases (such as in tumours near vital organs such as the brain or liver), or cause side effects. So modern oncology requires a carrier vehicle that would allow the targeted release of such potent chemicals, locking them away within some form of shell or bubble to allow the healthy cells and normal organs to escape them completely.

2. The Hidden World of the Tumour Microenvironment

Before you see why traditional treatments don't work, you need to see what makes the growing tumour uniquely different physically and biologically from surrounding tissue. Cancer begins with unregulated growth of cells, driven by genetic mechanisms. The tumour expands past about 1-2 millimetres and the growing interior cells can't receive enough nutrients and discard enough waste through diffusion by passive local blood supply. The resulting 'starved' tumour environment becomes hypoxic (lacks oxygen), extracellularly acidic, and subject to increased interstitial fluid pressure.

In response, growing tumours can secrete growth signals such as VEGF (vascular endothelial growth factor) and produce new blood vessels, known as angiogenesis. These tumour-associated blood vessels, however, are highly inefficient and haphazard, with loose interendothelial connections and gaps ranging from 100 nm to greater than 1000 nm. In addition to that, expanding tumour tissue lack of organized drainage pathways, with absence of functioning lymphatic vessels. This combination of inefficient vascular barrier and lack of drainage results in a principal phenomenon: The Enhanced Permeability and Retention Effect (EPR effect). Circulating nanoparticles of a defined size passively leaks out of tumour blood vessels due to EPR and accumulates in tumour tissue.

However, passive delivery alone rarely clears a growing tumour entirely. Once loaded, the nanoparticle in question is exposed to the high interstitial fluid pressure which creates a physical block to extensive molecular diffusion, and also a dense surrounding stroma comprised of type 1 collagen-rich tissue and unspecific immune cells (such as tumour-associated macrophages and myeloid-derived suppressor cells) that impedes molecules distribution. These cells in the slow growing tumour interior are not reached, leading local regrowing, and metastases. Thus, targeted delivery to deep molecular levels must include the application of a specific and targeted external force to drive the therapeutic carriers into this barrier. Magnetic precision targeting is needed to bridge this gap

3. Engineering the Perfect Nanoparticle: Core and Coating

These intelligent multi-layered constructs for oncology are manufactured within a narrow hydrodynamic window from ten to one hundred nanometres in size. This size range is essential for in vivo effectiveness; less than ten nanometres, it is filtered from the body and eliminated by the kidney; more than one hundred nanometres and it is rapidly and efficiently captured and cleared from the bloodstream and tissues by the reticuloendothelial immune system, where it concentrates in the spleen and liver. Within this range, it is small enough to evade premature clearance by the kidney, to effectively utilize the EPR effect and carry an active payload, but it remains sufficiently large to possess a significant respond to external magnetic fields. The core nanoparticle works like the nanoparticle engine driving the magnetic effect of the entire construct. Preferred for human clinic: The leading candidates are iron oxide nanoparticles of magnetite and maghemite due to the proven safety, biodegradation and reliable magnetic response characteristics of the particles. Under a critical core size (typically less than fifteen to twenty nanometres in diameter), these materials exhibit a phenomenon known as superparamagnetism. Normally, the magnetic dipoles within the core oscillate and align themselves in random directions every nanosecond (thermal fluctuation). As there is no residual net magnetization, the nanoparticles remain as separate individuals in the blood stream and do not agglomerate to clog blood vessels. However, the magnetic dipoles align themselves perfectly with an externally applied magnetic field producing a localized magnetic field which can be controlled and is responsive to the presence of external field: once the external field is switched off the magnetic dipoles snap back to their disordered positions and the magnetism is switched off instantaneously.

Encapsulating the toxic and reactive iron oxide core. An inert, functional coating is added over the iron oxide to prevent immune responses and adsorption of proteins to its surface. An uncoated nanoparticle is a highly hydrophobic, energetically favourable surface which readily adheres plasma proteins triggering a macrophage response and the nanoparticles clump together. A coating layer of biocompatible material (hydrophilic polymer or a surfactant) is added to provide an inert, shielded environment to prevent adsorption of proteins and to increase circulation time in vivo. By far the most common polymer coating used is PEG, however, natural polysaccharides (dextran or chitosan) can be used and include the ability to anchor drugs via chemical linkages. Functionally active targeting tags (custom antibodies, peptides or molecules like folic acid) which specifically binds to cancer cell surface receptors can also be introduced into the surface coating.

4. Step-by-Step: The Journey of a Magnetic Nanoparticle

For stage one, the therapeutic compound is synthetically assembled in the lab with powerful chemotherapy agents (like doxorubicin or paclitaxel) bound to a protective hydrophilic coating of polymers that encircle a superparamagnetic nanoparticle by “smart” linkers, only chemically susceptible to break down in acidic or enzyme-specific environments within the tumour tissue. The intact nanoparticles-drug conjugate is injected in stage two into the bloodstream where it circulates in the body. The hydrophilic shell on the outside prevent nanoparticle aggregation and reduces the likelihood of being detected early by circulating white blood cells. In stage three, an external high gradient magnet such as a rare earth permanent magnet or a regulated electromagnet is positioned over the solid tumour located in an externally-determined anatomical position of the patient's body.

As the particles reach this external magnetic field in stage four and circulate near the solid tumour the superparamagnetic nanoparticles polarize, their travel through the circulatory system counterbalanced by the external magnetic forces directed toward the wall of the circulation path where they cross through larger vessel endothelial gaps into the tumour tissue stroma. In stage five, once the nanoparticles embed themselves into the tumour microenvironment, the targeting ligands attached to the external nanoparticle surface bind to the receptor targets on the cancer cell surface. This initiates an active process by which the cell membrane folds around the nanoparticle in what is termed receptor-mediated endocytosis, the complex is then engulfed and internalized within an endosome, a vesicle within the cell. Finally, in stage six, the endosome develops into a more acidic compartment, the lysosome, wherein the extreme acidity or other enzymatic degradative processes that cleave the linkers, liberates the active therapeutic drug into the cytoplasm of the cell for entry into the cell nucleus to disrupt cell division and induce death.

5. Medical Applications: From Smart Drug Delivery to Hyperthermia

Medical applications based on magnetic nanoparticles use external magnetic fields to control the movement of the superparamagnetic core. Perhaps the most studied application is site-specific targeting and delivery of cancer drugs. The aim of this method is to avoid exposing the healthy organs of patients to the toxic effects of chemotherapy. By attaching a cancer drug to the magnetic core, doctors deliver the compound to the targeted site without causing damage throughout the system.

Attaching drugs to a core not only increases the local drug concentration at the tumour site, but it also drastically decreases systemic drug concentration – there are no problems like bone marrow suppression and widespread liver or kidney damage which often lead the oncologist to interrupt therapy.

The second most studied therapeutic application is based on magnetic hyperthermia. In this type of therapy, superparamagnetic nanoparticles are subjected to an oscillating magnetic field rather than a static one. Under the effect of the oscillating field, the orientation of the magnetic moments within the core continuously oscillates to synchronize with the changing field, inducing heat generation through two main processes: Nel relaxation and Brownian relaxation. Nel relaxation is caused by the rotation of the magnetic moments within the core, while Brownian relaxation arises from the random motion of the particle in solution.

Doctors use frequency and power control to generate local heating in the tumour region to 42-46 degrees Celsius. Since cancer cells produce their own heat through their acidic and inefficient blood vessels (which can't adequately disperse heat), high temperatures can denature proteins and kill them without harming normal tissue.

In addition to therapy, iron oxide nanoparticles are used in diagnostic imaging as powerful MRI contrast agents. High magnetic susceptibility of superparamagnetic cores affects water proton spins by accelerating T2 relaxation time – the transverse relaxation time for proton spins which allows nanoparticles to create negative contrast in MR images. As a result, radiologists can visualize tiny groups of cancer cells and even single cancer cells and micro metastases invisible on contrast-free MR scans. This leads to unprecedented detail of tissue structures.

The final goal of research is theranostics: a combination of targeted ligands, therapeutic drugs, and a contrast agent integrated into a single nanocarrier. Such a nanodevice will enable simultaneous visualization of the boundaries of a tumour using MRI, accumulation of a therapeutic agent using an external magnetic field, triggered thermal killing of the tumour using magnetic hyperthermia and imaging monitoring of tumour progression.

6. Advantages Over Conventional Therapies

Magnetic Targeting Enables Breakthroughs in Four Key Areas of Cancer Treatment Traditional treatment relies on a strategy of indiscriminate chemical weapons: to ensure a few molecules of the medicine reach the tumour, the rest are distributed all over the patient's body where they wreak havoc on all healthy organ systems. Magnetic targeting is radically different: thanks to external magnetic fields that keep the medicine particles immobilized at a designated location within the body, the medication remains strictly targeted. This site-specificity has implications for the volume of medicine needed: conventional treatment requires exceptionally high concentrations of medicine dispersed systemically in order to provide a therapeutic dose at the tumour; magnetic targeting uses much lower concentrations because all the medicine is directed exactly to where it's needed.

This translates to radically decreased off-target side effects: the system poisoning associated with standard chemotherapy results in side effects such as baldness, severe nausea and organ damage to virtually all systems of the body. Magnetic targeting avoids the widespread collateral damage to healthy peripheral tissue by precisely directing the medicine, causing minimal discomfort or adverse reactions for patients. Patients can better tolerate the entire regimen without suffering complications such as treatment gaps due to illness from poisoning, or missed sessions. And whereas conventional medicine treatment relies on formulaic, mass prescription that's based strictly on the patient's weight, magnetic targeting allows a personalized therapy approach that can be modified with the guidance of live medical imagery.

7. Current Research Frontiers and Clinical Translation

In magnetic nanoparticles research, the arena is fast shifting from simple lab chemistry to sophisticated clinical biology. Magnetic targeting of drugs in vivo has been extremely effective in a wide range of animal models, from simple tumour-bearing rodents to large animals, achieving profound reductions in tumour size and substantially extended survival times for several aggressively growing cancers, including glioblastoma multiforme (brain), triple-negative breast cancer, liver cancer (hepatocellular carcinoma), and advanced prostate cancer. Many of the ongoing scientific pursuits are focused on designing multimodal therapeutic delivery systems that integrate multiple treatments into a single treatment paradigm. Researchers are attempting to integrate magnetic hyperthermia with immunotherapy, whereby the local heat delivered by the magnetic nanoparticles stimulates death of cancer cells, which subsequently release their tumour-specific antigens into the microenvironment, signalling to the immune system that there is an 'alarm' in this vicinity, making the otherwise invisible tumours obvious targets for the body's circulating immune cells.

The idea is that systemically delivered immune cells will travel to this vicinity and attack the tumour, as well as remote untreated cancer cells disseminated throughout the body. The team is also trying to integrate magnetic targeting, photothermal therapy (using near infrared lasers) and conventional chemotherapy, to develop multimodal and multi-attack therapeutic regimes targeting tumours from multiple vectors simultaneously. The vast majority of these magnetic nanoparticles directed therapies are, as yet, under preclinical or early clinical trials and are not standard medical treatment. It remains challenging to translate these therapies for human use as it involves scaling the complexities of laboratory processes to a patient's body volume and circulatory systems and requiring methodical, careful, one-step at a time, process optimization for a normal hospital setting.

8. Critical Challenges, Bottlenecks, and Limitations

Overcoming these biological, engineering, and regulatory obstacles to bring these magnetic nanoparticles to a patient bed is key. When nanoparticles enter the blood stream, they encounter the immune system. Even with a coating of polyethylene glycol (PEG), particles will be picked up by liver and spleen macrophages and accumulate in the reticuloendothelial system (RES). This may limit treatment efficacy while also posing an additional threat in the long term because the iron oxide core will ultimately degrade in lysosomes to iron ions that can cause oxidative stress via the Fenton reaction (producing damaging reactive oxygen species) to lead to tissue and organ damage.

A basic physical constraint of magnetic manipulation is the steep decay of magnetic field strength with distance because magnetic force is inversely proportional to the cube of the distance. This works quite well for targeting surface tissues like breast or skin cancers but not so well for the manipulation of nanoparticles within deep tissues-such as those in the liver or pancreas-that are moving at high speed, so engineers still face a huge challenge to induce sufficient magnetic forces. It also pushes the limits of chemical engineering to scale-up production of these nanoparticles with identical cores sizes, uniform coatings, and uniform drug loads. And on the regulatory front, approval of nanomedicines is notoriously difficult. Regulators view the nanomedicine platform-a diagnostic agent, complex vehicle, and a chemotherapy-as a combination product and expect each component part of the nanomedicine to be tested independently and the combined device as well. The huge costs of building a manufacturing facility compliant with current Good Manufacturing Practices, along with immense expenses associated with clinical trials, are major impediments to commercial development.

9. Future Horizons and Directions in Nanomedicine

In order to get around these engineering and biological hurdles, next-generation nanomedicine is targeting the development of clever, hyper-reactive nanoparticle systems. Engineers and researchers are engineering sophisticated multi-stimuli-responsive nanomaterials that dynamically adjust their behaviour as their environment changes.

These particles are entirely dormant as they flow through healthy vasculature, but the second they're exposed to a unique trigger profile-such as the low pH of the tumour core plus an externally generated magnetic field or a targeted pulse of ultrasound-they shape-shift or release their precious cargo of drugs. Further integrations with precision oncology and image-guided treatment delivery systems mean that these targeted release mechanisms would activate precisely where and when they are needed. Beyond their drug-delivery potential, another fascinating use of magnetic nanoparticles is to serve as highly specialized transports for gene therapy. Instead of ferrying toxic, conventional chemotherapy drugs, these nano-vehicles carry genetic cargo - Small Interfering RNAs or the full suite of CRISPR-Cas9 genome editing tools, for example - and clinicians will use external magnets to steer the particles through circulation and directly into the nucleus of cancer cells, where they can inactivate cancer-promoting oncogenes or repair DNA mutations. Still further on the horizon, robotics and nanotechnology are becoming intertwined, as researchers develop nascent magnetically actuated micro- and nano- robots that, rather than drifting with blood flow, use a carefully shaped rotating external magnetic field to swim through bodily fluids and penetrate dense tumour tissue.

In tandem with real-time, ultra-high-resolution imaging, the cancer care of the future, driven by active nanobots and the principles of precision oncology, could operate in an entirely non-invasive, autonomous fashion, targeting minuscule cancer cell clusters before they've even formed detectable tumours.

10. Ethical, Safety, and Regulatory Frameworks

As magnetic nanoparticles approach mainstream clinical use, it's vital to address the unique safety and ethical concerns these tools raise. Medically, the most urgent challenge is to precisely define where these engineered molecules end up in the human body and determine how long it takes for them to be safely flushed out of the system.

Given the way synthetic nanoparticles interact with biology at the molecular level, conventional toxicological assays may fall short. New methods of toxicity screening will be required to detect potentially subtle long-term adverse effects, such as immune system activation, DNA damage in healthy cells, or iron overload in key organs over the course of several years. The high cost of advanced nano therapies poses a significant ethical concern for society: developing and producing these personalized theranostic nanoparticles requires a high degree of expertise and sophisticated manufacturing facilities. The costs of production could make such life-saving treatment unavailable to all but the wealthy, and disparities in access to this technology will be stark if development goes unchecked.

Strict informed consent processes will need to be implemented in any clinical trials so that trial participants truly understand the experimental nature of this nanomedicine technology. It will therefore be just as important to figure out how to produce these sophisticated particles at an accessible cost as it will be to discover ways to increase their clinical effectiveness, lest we create two-tiered systems of cancer care. 11. Conclusion Magnetically directed nanoparticle systems mark a new era in the history of cancer medicine - the era of targeted therapy. They offer an evolutionary leap from the brute force methods we have historically applied, moving toward more elegant and precisely aimed attacks against individual cells.

By leveraging the magnetic properties of their superparamagnetic iron oxide cores, scientists have developed a system that can navigate through tumour microenvironments in ways that were previously impossible, breaking through a biological shield that has long protected the most aggressive and difficult-to-treat cancer forms. The combined application of targeted drug delivery, local hyperthermia-induced cell killing, and high-resolution MR image guidance in a single nanoplatform provides a tantalizing glimpse into the future of personalized and precise cancer therapy, or theranostics. Of course, before magnetic nanoparticles are used in the clinic, researchers will have to surmount a number of important technological challenges.

Although their magnetic-guidance system represents an enormous stride forward toward eliminating side effects while ensuring delivery efficiency, clinical trials will be needed to evaluate effectiveness in humans. The factors that cause our immune systems to rapidly clear nanoparticles from the body-their rapid removal by the liver and spleen-must be overcome. We need to be able to effectively guide magnetic fields deep into the human body to target remote or in-accessible areas of tumours, and it must be possible to mass-produce these intricate nanoparticles on a regulatory-compliant basis. Once multi-modal targeting capabilities are integrated into sophisticated, smart nanomaterials that are proven through rigorous clinical trials, magnetically directed nanoparticles are poised to become an indispensable part of the future landscape of precision cancer therapies, offering a kinder, far more effective and individualized approach to treatment.

References

1. Alexiou, C., Schmid, R. J., Jurgons, R., Kremer, M., Wanner, G., Bergemann, C., ... & Parak, F. G. (2006). Targeting cancer with magnetic nanoparticles. *European Biophysics Journal*, 35(5), 446-450.
2. DeNardo, S. J., DeNardo, G. L., Natarajan, A., Miers, L. A., Foreman, A. R., Gruettner, C., ... & Yuan, A. (2007). Thermal bio-nanomedicine of cancer: The role of targeted magnetic nanoparticles. *Journal of Nuclear Medicine*, 48(3), 437-444.
3. Dobson, J. (2006). Gene transfer therapy using magnetic nanoparticles. *Gene Therapy*, 13(4), 283-287.
4. Gupta, A. K., & Gupta, M. (2005). Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials*, 26(18), 3995-4021.
5. Ito, A., Shinkai, M., Honda, H., & Kobayashi, T. (2005). Medical application of magnetic nanoparticles. *Journal of Bioscience and Bioengineering*, 100(1), 1-11.
6. Jordan, A., Scholz, R., Maier-Hauff, K., Johannsen, M., Wust, P., Nadobny, J., ... & Felix, R. (2001). Presentation of a new magnetic field therapy system for the treatment of human solid tumours with magnetic fluid hyperthermia. *Journal of Magnetism and Magnetic Materials*, 225(1-2), 118-126.
7. Laurent, S., Saei, A. A., Mahmoudi, M., & Häfeli, U. O. (2014). Superparamagnetic iron oxide nanoparticles for biomedical applications: A focus on progress and challenges. *Expert Opinion on Drug Delivery*, 11(9), 1449-1470.
8. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumour vascular permeability and the EPR effect in macromolecular therapeutics: A review. *Journal of Controlled Release*, 65(1-2), 271-284.
9. Mahmoudi, M., Sant, S., Wang, B., Laurent, S., & Sen, T. (2011). Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modifications, and applications in chemotherapy. *Advanced Drug Delivery Reviews*, 63(14-15), 1322-1346.

10. Neuberger, T., Schöpf, B., Hofmann, H., Hofmann, M., & von Rechenberg, B. (2005). Clinical applications of magnetic nanoparticles. *Journal of Magnetism and Magnetic Materials*, 293(1), 483-496.
11. Pankhurst, Q. A., Connolly, J., Jones, S. K., & Dobson, J. (2003). Applications of magnetic nanoparticles in biomedicine. *Journal of Physics D: Applied Physics*, 36(13), R167.
12. Sun, C., Lee, J. S., & Zhang, M. (2008). Magnetic nanoparticles in cancer theranostics. *Advanced Drug Delivery Reviews*, 60(11), 1252-1265.
13. Torchilin, V. P. (2011). Tumour delivery of macromolecular drugs based on the EPR effect. *Advanced Drug Delivery Reviews*, 63(3), 131-135.
14. Wahajuddin, & Arora, S. (2012). Superparamagnetic iron oxide nanoparticles: Magnetic nanoplatforms as drug carriers. *International Journal of Nanomedicine*, 7, 3445-3471.
15. Yoo, D., Lee, J. H., Shin, T. H., & Cheon, J. (2011). Theranostic magnetic nanoparticles. *Accounts of Chemical Research*, 44(10), 863-874.